Meeting
2014 ASCO Annual Meeting
Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma.
Authors
Eugene Kennedy
NewLink Genetics, Ames, IA
Eugene Kennedy , Gabriela R. Rossi , Nicholas N. Vahanian , Charles J. Link
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02073123
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9117)
DOI
10.1200/jco.2014.32.15_suppl.tps9117
Abstract #
TPS9117
Poster Bd #
313B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia
Poster
2023 ASCO Annual Meeting
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
First Author: Peter Kar Han Lau
Poster
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
First Author: Howard Kaufman
Poster
2022 ASCO Annual Meeting
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
First Author: Greg Andrew Durm